JP2024501831A5 - - Google Patents
Info
- Publication number
- JP2024501831A5 JP2024501831A5 JP2023538969A JP2023538969A JP2024501831A5 JP 2024501831 A5 JP2024501831 A5 JP 2024501831A5 JP 2023538969 A JP2023538969 A JP 2023538969A JP 2023538969 A JP2023538969 A JP 2023538969A JP 2024501831 A5 JP2024501831 A5 JP 2024501831A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- item
- tcr
- acid molecule
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129829P | 2020-12-23 | 2020-12-23 | |
| US63/129,829 | 2020-12-23 | ||
| US202163225821P | 2021-07-26 | 2021-07-26 | |
| US63/225,821 | 2021-07-26 | ||
| US202163250329P | 2021-09-30 | 2021-09-30 | |
| US63/250,329 | 2021-09-30 | ||
| US202163257345P | 2021-10-19 | 2021-10-19 | |
| US63/257,345 | 2021-10-19 | ||
| PCT/US2021/065069 WO2022140665A1 (en) | 2020-12-23 | 2021-12-23 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501831A JP2024501831A (ja) | 2024-01-16 |
| JP2024501831A5 true JP2024501831A5 (enExample) | 2024-12-04 |
Family
ID=82160130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538969A Pending JP2024501831A (ja) | 2020-12-23 | 2021-12-23 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240117002A1 (enExample) |
| EP (1) | EP4267733A4 (enExample) |
| JP (1) | JP2024501831A (enExample) |
| AU (1) | AU2021410788A1 (enExample) |
| CA (1) | CA3203180A1 (enExample) |
| WO (1) | WO2022140665A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| WO2024054425A1 (en) * | 2022-09-08 | 2024-03-14 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2018232020A1 (en) * | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2021505131A (ja) * | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| US20200399383A1 (en) * | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| MX2020009371A (es) * | 2018-03-09 | 2021-01-08 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| WO2020198033A1 (en) * | 2019-03-22 | 2020-10-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
-
2021
- 2021-12-23 US US18/269,214 patent/US20240117002A1/en active Pending
- 2021-12-23 EP EP21912227.2A patent/EP4267733A4/en active Pending
- 2021-12-23 WO PCT/US2021/065069 patent/WO2022140665A1/en not_active Ceased
- 2021-12-23 AU AU2021410788A patent/AU2021410788A1/en not_active Abandoned
- 2021-12-23 CA CA3203180A patent/CA3203180A1/en active Pending
- 2021-12-23 JP JP2023538969A patent/JP2024501831A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404492B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| AU2018202294B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| JP2023503163A5 (enExample) | ||
| WO2018059549A1 (en) | Immune effector cell therapies with enhanced efficacy | |
| JP2024501831A5 (enExample) | ||
| JP2021515598A5 (enExample) | ||
| JP2023515211A5 (enExample) | ||
| JP2018515123A5 (enExample) | ||
| JP2022548866A5 (enExample) | ||
| US20230192848A1 (en) | Engineered cell compositions and methods of use thereof | |
| JP2021530971A (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP2022521278A (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| JP2024515181A5 (enExample) | ||
| US12565658B2 (en) | CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies | |
| CN118048312A (zh) | 靶向cd19和/或cd20的car-nk细胞及其制备与应用 | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| HK40077730B (zh) | 核酸、包含其的工程免疫细胞及其制备方法和用途 | |
| HK1248273B (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| HK1248273A1 (en) | Methods for enhancing efficacy of therapeutic immune cells |